A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

NCT02418559 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: JNJ-63623872 (300 mg)
DRUG: JNJ-63623872 (600 mg)
DRUG: JNJ-63623872 (1200 mg)
DRUG: Placebo

Sponsor

Janssen Infectious Diseases BVBA